Níveis séricos da IL-13 na esclerose sistêmica: uma revisão sistemática com meta-análise / Serum levels of IL-13 in systemic sclerosis: a systematic review with meta-analysis

A interleucina-13 (IL-13) sérica foi investigada na esclerose sistêmica (ES) por meio de uma meta-análise para avaliar a possível diferença nos níveis em pacientes com a doença e pessoas saudáveis. As buscas foram realizadas nas bases de dados Pubmed, ScienceDirect, Cochrane Library, LILACS e Scopus para estudos do tipo caso-controle pertinentes utilizando os descritores. Os níveis séricos dos pacientes com ES em relação aos controles saudáveis foram plotados usando o software Review Manager 5.3. A avaliação da qualidade de cada estudo elegível foi conduzida na Escala de Newcastle-Ottawa (NOS). Quatro estudos de caso-controle foram selecionados para esta meta-análise e continham um total de 120 pacientes com ES e 84 controles saudáveis. Nossos resultados demonstram níveis séricos elevados da IL-13 em pacientes com ES, com um agrupamento médio de 0,70 ng/ml (p=0,00001) (IC 95%: -0,42 a -0,99, p=0,6). A IL-13 está aumentada no soro de pacientes com ES em comparação com os controles saudáveis e pode ser útil como possível biomarcador da doença. 

Single Nucleotide Polymorphisms at +191 and +292 of Galectin-3 Gene (LGALS3) Related to Lower GAL-3 Serum Levels Are Associated with Frequent Respiratory Tract Infection and Vaso-Occlusive Crisis in Children with Sickle Cell Anemia

Submitted by Adagilson Silva ([email protected]) on 2017-06-05T13:08:05Z No. of bitstreams: 1 27603703 2016 men-sin.oa.PDF: 1008770 bytes, checksum: 82f0081628ade062bc08ce6be5782a03 (MD5)Approved for entry into archive by Adagilson Silva ([email protected]) on 2017-06-05T13:08:29Z (GMT) No. of bitstreams: 1 27603703 2016 men-sin.oa.PDF: 1008770 bytes, checksum: 82f0081628ade062bc08ce6be5782a03 (MD5)Made available in DSpace on 2017-06-05T13:08:29Z (GMT). No. of bitstreams: 1 27603703 2016 men-sin.oa.PDF: 1008770 bytes, checksum: 82f0081628ade062bc08ce6be5782a03 (MD5) Previous issue date: 2016Programa de Doutorado da Rede Nordeste de Biotecnologia. Recife, PE, Brasil.Universidade de Pernambuco. Instituto de Ciências Biológicas e Faculdade de Ciências Médicas. Recife, PE, Brasil.Universidade de Pernambuco. Instituto de Ciências Biológicas e Faculdade de Ciências Médicas. Recife, PE, Brasil.Universidade Federal de Pernambuco. Laboratório de Imunomodulação e Novas Abordagens Terapêutica (LINAT). Recife, PE, Brasil.Universidade de Pernambuco. Instituto de Ciências Biológicas e Faculdade de Ciências Médicas. Recife, PE, Brasil.Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.Fundação Hematologia e Hemoterapia de Pernambuco (HEMOPE). Recife, PE, Brasil.Universidade Federal de Pernambuco. Departamento de Ciências Biológicas. Recife, PE, Brasil.Universidade Federal de Pernambuco. Laboratório de Imunomodulação e Novas Abordagens Terapêutica (LINAT). Recife, PE, Brasil.Universidade Federal de Pernambuco. Departamento de Ciências Biológicas. Recife, PE, Brasil.Fundação Hematologia e Hemoterapia de Pernambuco (HEMOPE). Recife, PE, Brasil.Universidade Federal de Pernambuco. Laboratório de Imunomodulação e Novas Abordagens Terapêutica (LINAT). Recife, PE, Brasil.Programa de Doutorado da Rede Nordeste de Biotecnologia. Recife, PE, Brasil / Universidade de Pernambuco. Instituto de Ciências Biológicas e Faculdade de Ciências Médicas. Recife, PE, Brasil.Programa de Doutorado da Rede Nordeste de Biotecnologia. Recife, PE, Brasil / Universidade de Pernambuco. Instituto de Ciências Biológicas e Faculdade de Ciências Médicas. Recife, PE, Brasil.Patients with sickle cell anemia (SCA) may present chronic hemolytic anemia, vaso-occlusion and respiratory tract infection (RTI) episodes. Galectin-3 (GAL-3) is a multifunctional protein involved in inflammation, apoptosis, adhesion and resistance to reactive oxygen species. Studies point to a dual role for GAL-3 as both a circulation damage-associated molecular pattern and a cell membrane associated pattern recognition receptor

Clinical data of children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.

<p>Clinical data of children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.</p

Serum galectin-3 levels are associated with <i>LGALS3</i> +191 and +292 combined genotypes in children with SCA.

<p>Statistical analysis of <i>LGALS3</i> combined genotype related of galectin-3 levels (high, intermediate and low) in which the serum concentrations in ng/ml were compared using Kruskal-Wallis test. High vs. intermediate: <i>p =</i> 0.1687; high vs. low: <i>p =</i> 0.0002; high vs. intermediate+low: <i>p</i> = 0.0098.</p

Serum galectin-3 levels associated with <i>LGALS3</i> +191 (A) and +292 (B) genotypes in children with SCA.

<p><i>LGALS3</i> +191: C = reference allele; A = variant allele; <i>LGALS3</i> +292: A = reference allele; C = variant allele; +191 genotypes: CC vs. CA: <i>p <</i>0.0001; CC vs. AA: <i>p <</i>0.0001; CC vs. AA+CA: <i>p</i> <0.0001. +292 genotypes: AA vs. AC: <i>p</i> = 0.1684; AA vs. CC: <i>p</i> = 0.0046; AA vs. CC+AC: <i>p</i> = 0.0136. Mann-Whitney tests.</p

<i>LGALS3</i> +191 and +292 diplotype of serum levels with vaso-occlusive crisis and respiratory tract infection in children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.

<p><i>LGALS3</i> +191 and +292 diplotype of serum levels with vaso-occlusive crisis and respiratory tract infection in children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.</p

<i>LGALS3</i> +191 and +292 with vaso-occlusive crisis and respiratory tract infection in children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.

<p><i>LGALS3</i> +191 and +292 with vaso-occlusive crisis and respiratory tract infection in children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.</p

<i>LGALS3</i> +191 and +292 combined genotype distribution with vaso-occlusive crisis and respiratory tract infection in children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.

<p><i>LGALS3</i> +191 and +292 combined genotype distribution with vaso-occlusive crisis and respiratory tract infection in children with sickle cell anemia attended in Hemope Foundation—Recife/Brazil.</p

Single Nucleotide Polymorphisms at +191 and +292 of Galectin-3 Gene (<i>LGALS3</i>) Related to Lower GAL-3 Serum Levels Are Associated with Frequent Respiratory Tract Infection and Vaso-Occlusive Crisis in Children with Sickle Cell Anemia

<div><p>Introduction</p><p>Patients with sickle cell anemia (SCA) may present chronic hemolytic anemia, vaso-occlusion and respiratory tract infection (RTI) episodes. Galectin-3 (GAL-3) is a multifunctional protein involved in inflammation, apoptosis, adhesion and resistance to reactive oxygen species. Studies point to a dual role for GAL-3 as both a circulation damage-associated molecular pattern and a cell membrane associated pattern recognition receptor.</p><p>Objective</p><p>To investigate associations between the SNPs of GAL-3 gene (<i>LGALS3</i>) and serum levels with RTI and vaso-occlusive crisis (VOC) in children with SCA.</p><p>Materials and Methods</p><p>SNPs +191 and +292 in <i>LGALS3</i> were studied using the TaqMan real-time PCR system; GAL-3 serum levels were measured by ELISA. The study included 79 children with SCA ranging from 2 to 12 years old.</p><p>Results</p><p>GAL-3 serum levels were associated with <i>LGALS3</i> +191 and +292 genotypes (<i>p</i> <0.0001; <i>p</i> = 0.0169, respectively). <i>LGALS3</i> +191, AA genotype was associated with low and CC with higher levels of GAL-3. For <i>LGALS3</i> +292, the CC genotype was associated with lower GAL-3 and AA with higher levels. Patients with Frequency of RTI (FRTI) ≥1 presented higher frequency of +191AA (<i>p</i> = 0.0263) and +292AC/CC genotypes (<i>p</i> = 0.0320). SNP +292 was associated with Frequency of VOC (FVOC) (<i>p</i> = 0.0347), whereas no association was shown with SNP +191 and FVOC. However, CA/AC and AA/CC genotypes with lower GAL-3 levels showed a higher frequency in patients with FRTI ≥1 (<i>p</i> = 0.0170; <i>p</i> = 0.0138, respectively). Also, patients with FVOC ≥1 presented association with CA/AC (<i>p</i> = 0.0228). <i>LGALS3</i> +191 and +292 combined genotypes related to low (<i>p</i> = 0.0263) and intermediate expression (<i>p</i> = 0.0245) were associated with FRTI ≥1. Lower GAL-3 serum levels were associated with FRTI ≥1 (<i>p</i> = 0.0426) and FVOC ≥1 (<i>p</i> = 0.0012).</p><p>Conclusion</p><p>Variation of GAL-3 serum levels related to SNPs at +191 and +292 may constitute a susceptibility factor for RTI and VOC frequency.</p></div